Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;29(4):1504-1517.
doi: 10.1007/s12350-021-02790-9. Epub 2021 Sep 2.

Multimodality imaging to distinguish between benign and malignant cardiac masses

Ayaz Aghayev  1 , Michael K Cheezum  2 , Michael L Steigner  3 , Negareh Mousavi  4 , Robert Padera  5 , Ana Barac  6 , Raymond Y Kwong  7 , Marcelo F Di Carli  8 , Ron Blankstein  8
Affiliations

Multimodality imaging to distinguish between benign and malignant cardiac masses

Ayaz Aghayev et al. J Nucl Cardiol. 2022 Aug.

Abstract
in English, Chinese, Spanish

Background: To compare the diagnostic accuracy of CMR and FDG-PET/CT and their complementary role to distinguish benign vs malignant cardiac masses.

Methods: Retrospectively assessed patients with cardiac mass who underwent CMR and FDG-PET/CT within a month between 2003 and 2018.

Results: 72 patients who had CMR and FDG-PET/CT were included. 25 patients (35%) were diagnosed with benign and 47 (65%) were diagnosed with malignant masses. 56 patients had histological correlation: 9 benign and 47 malignant masses. CMR and FDG-PET/CT had a high accuracy in differentiating benign vs malignant masses, with the presence of CMR features demonstrating a higher sensitivity (98%), while FDG uptake with SUVmax/blood pool ≥ 3.0 demonstrating a high specificity (88%). Combining multiple (> 4) CMR features and FDG uptake (SUVmax/blood pool ratio ≥ 3.0) yielded a sensitivity of 85% and specificity of 88% to diagnose malignant masses. Over a mean follow-up of 2.6 years (IQR 0.3-3.8 years), risk-adjusted mortality were highest among patients with an infiltrative border on CMR (adjusted HR 3.1; 95% CI 1.5-6.5; P = .002) or focal extracardiac FDG uptake (adjusted HR 3.8; 95% CI 1.9-7.7; P < .001).

Conclusion: Although CMR and FDG-PET/CT can independently diagnose benign and malignant masses, the combination of these modalities provides complementary value in select cases.

背景: 本研究旨在比较心脏磁共振 (CMR) 和FDG-PET/CT的诊断准确性及其在鉴别心脏良恶性肿瘤中的互补作用。 方法: 本研究回顾性地纳入了2003-2018年间在本中心被诊断为心脏肿瘤的患者, 所有患者CMR和FDG-PET/CT检查均在一个月内完成。 结果: 本研究纳入了72例同时接受了CMR和FDG-PET/CT检查的患者。其中25例 (35%) 患者被诊断为心脏良性肿瘤, 47例 (65%) 患者被诊断为心脏恶性肿瘤。在所有72例患者中, 56例 (9例良性和47例恶性) 有组织学诊断的证据。CMR和FDG-PET/CT在鉴别心脏良性和恶性肿瘤方面具有较高的准确性。其中CMR的特点表现为较高的敏感性 (98%), 而当FDG摄取为SUVmax/血池≥ 3.0时, FDG-PET/CT有较高的特异性 (88%)。结合多种CMR特征 (> 4种) 和FDG摄取程度 (SUVmax/血池比率≥ 3.0) 用于心脏恶性肿瘤的诊断时, 其敏感性为85%, 特异性为88%。平均随访2.6年后 (IQR:0.3-3.8年), CMR表现为边界浸润 (调整后HR=3.1; 95%可信区间: 1.5-6.5; p=0.002) 或局灶性心脏外FDG摄取 (校正HR=3.8; 95%可信区间: 1.9-7.7; p<0.001) 的患者, 风险校正后的死亡率最高。 结论: 尽管CMR和FDG-PET/CT可以独立地用于诊断心脏良性和恶性肿瘤, 但在某些特定病例中, 将这两种方法结合具有互补的诊断价值。.

Antecedentes: Comparar la precisión diagnóstica de la RMC y del PET/CT con FDG y su función complementaria para distinguir entre masas cardíacas benignas y malignas. MéTODOS: Pacientes evaluados retrospectivamente con masas cardíacasque se sometieron a RMC y a PET/CT con FDG en un periodo de 1 mes entre 2003-2018.

Resultados: Se incluyeron 72 pacientes a los que se les realizó RMC y PET/CT con FDG. 25 pacientes (35%) fueron diagnosticados como masas benignas y 47 (65%) como masas malignas. 56 pacientes tuvieron correlación histológica: 9 masas benignas y 47 malignas.La RMC y el PET/CT con FDG tuvieron una alta precisión en la diferenciación de masas benignas de malignas, algunas caracteristicas de la RMC demostraron una mayor sensibilidad (98 %), mientras que una captación de FDG (SUVmax/poolsanguíneo ≥ 3.0)demostró una alta especificidad (88%). Combinando múltiples (>4) características de la RMC con la captación de FDG (SUVmax/poolsanguíneo ≥ 3,0)se obtuvo una sensibilidad del 85% y una especificidad del 88 % para diagnosticar masas malignas. Durante un seguimiento promedio de 2.6 años (ICR: 0.3-3.8 años), la mortalidad ajustada por riesgo fue más alta entre los pacientes con un borde infiltrante en la RMC (HR ajustado = 3.1; IC del 95 %: 1.5-6.5;p=0.002) o captación extracardiaca focal de FDG (HR ajustado=3.8; IC 95%: 1.9-7.7; p<0.001). CONCLUSIóN: Aunque la RMC y el PET/CT con FDG pueden diagnosticar de forma independiente masas benignas y malignas, la combinación de estas modalidades proporciona un valor complementario en casos seleccionados.

Keywords: MRI; PET; modalities.

PubMed Disclaimer

Comment in

References

    1. Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T. Cardiac tumours: Diagnosis and management. Lancet Oncol 2005;6:219-28. https://doi.org/10.1016/S1470-2045(05)70093-0 - DOI - PubMed
    1. Mousavi N, Cheezum MK, Aghayev A, Padera R, Vita T, Steigner M et al. Assessment of cardiac masses by cardiac magnetic resonance imaging: Histological correlation and clinical outcomes. J Am Heart Assoc 2019;8:e007829. https://doi.org/10.1161/JAHA.117.007829 - DOI - PubMed - PMC
    1. Weinsaft JW, Kim HW, Shah DJ, Klem I, Crowley AL, Brosnan R et al. Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol 2008;52:148–157. https://doi.org/10.1016/j.jacc.2008.03.041 - DOI - PubMed
    1. Burke ARV Tumors of the heart and great vessels: Atlas of tumor pathology, 3rd edn1996; Armed Forces Institute of Pathology, Washington
    1. Abraham KP, Reddy V, Gattuso P. Neoplasms metastatic to the heart: Review of 3314 consecutive autopsies. Am J Cardiovasc Pathol 1990;3:195-98 - PubMed

MeSH terms

Substances

LinkOut - more resources